DE GIGLIO, ANDREA
DE GIGLIO, ANDREA
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Ricercatori a tempo determinato
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable
2019 Cortellini A.; Bersanelli M.; Buti S.; Cannita K.; Santini D.; Perrone F.; Giusti R.; Tiseo M.; Michiara M.; Di Marino P.; Tinari N.; De Tursi M.; Zoratto F.; Veltri E.; Marconcini R.; Malorgio F.; Russano M.; Anesi C.; Zeppola T.; Filetti M.; Marchetti P.; Botticelli A.; Antonini Cappellini G.C.; De Galitiis F.; Vitale M.G.; Rastelli F.; Pergolesi F.; Berardi R.; Rinaldi S.; Tudini M.; Silva R.R.; Pireddu A.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Iacono D.; Gelibter A.; Occhipinti M.A.; Parisi A.; Porzio G.; Fargnoli M.C.; Ascierto P.A.; Ficorella C.; Natoli C.
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report
2023 Li B.; Jia Z.; Huang Z.; Xue J.; Wang Y.; Guo C.; Si X.; Chen Z.; Li J.; Chen R.; Bie Z.; De Giglio A.; Christopoulos P.; Liang N.; Li S.
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
2022 Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G.
Advanced non-small-cell lung cancer: how to manage non-oncogene disease
2022 De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G.
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
2018 Ricciuti B.; Baglivo S.; De Giglio A.; Chiari R.
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances
2021 Tateo V.; Manuzzi L.; Parisi C.; De Giglio A.; Campana D.; Pantaleo M.A.; Lamberti G.
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
2020 Cortellini A.; Bersanelli M.; Santini D.; Buti S.; Tiseo M.; Cannita K.; Perrone F.; Giusti R.; De Tursi M.; Zoratto F.; Marconcini R.; Russano M.; Zeppola T.; Anesi C.; Filetti M.; Marchetti P.; Botticelli A.; Gelibter A.; De Galitiis F.; Vitale M.G.; Rastelli F.; Tudini M.; Silva R.R.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Migliorino M.R.; Mallardo D.; Vanella V.; Mosillo C.; Bracarda S.; Rinaldi S.; Berardi R.; Natoli C.; Ficorella C.; Porzio G.; Ascierto P.A.
Antibody–drug conjugates for lung cancer in the era of personalized oncology
2021 Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R.; Pirro M.
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer
2023 Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Prelaj A.; Lopez-Castro R.; Bosch-Barrera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar Nana F.; Ponce S.; Albarran-Artahona V.; Dal Maso A.; Spotti M.; Mielgo X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.B.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Mezquita L.; Planchard D.
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
2022 Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G.
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach
2021 De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A.
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients
2023 De Giglio A.; Deiana C.; Di Federico A.
Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies
2019 de Giglio A.; Nuvola G.; Gustavo Dall'Olio F.
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
2023 Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, Rita; Potena, Luciano
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities
2022 De Giglio A.; Orlando V.; Andrini E.; Ricciuti B.; Lamberti G.; Chiari R.
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics
2020 de Giglio A.; Nuvola G.; Baldini C.
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
2020 Ricciuti B.; Brambilla M.; Cortellini A.; De Giglio A.; Ficorella C.; Sidoni A.; Bellezza G.; Crino L.; Ludovini V.; Baglivo S.; Metro G.; Chiari R.
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
2023 Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A.
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5)
2020 Naqash A.R.; Ricciuti B.; Owen D.H.; Florou V.; Toi Y.; Cherry C.; Hafiz M.; De Giglio A.; Muzaffar M.; Patel S.H.; Sugawara S.; Burkart J.; Park W.; Chiari R.; Sugisaka J.; Otterson G.A.; de Lima Lopes G.; Walker P.R.
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable | Cortellini A.; Bersanelli M.; Buti S.; Cannita K.; Santini D.; Perrone F.; Giusti R.; Tiseo M.; M...ichiara M.; Di Marino P.; Tinari N.; De Tursi M.; Zoratto F.; Veltri E.; Marconcini R.; Malorgio F.; Russano M.; Anesi C.; Zeppola T.; Filetti M.; Marchetti P.; Botticelli A.; Antonini Cappellini G.C.; De Galitiis F.; Vitale M.G.; Rastelli F.; Pergolesi F.; Berardi R.; Rinaldi S.; Tudini M.; Silva R.R.; Pireddu A.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Iacono D.; Gelibter A.; Occhipinti M.A.; Parisi A.; Porzio G.; Fargnoli M.C.; Ascierto P.A.; Ficorella C.; Natoli C. | 2019-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | s40425-019-0527-y.pdf; 7782371.zip |
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report | Li B.; Jia Z.; Huang Z.; Xue J.; Wang Y.; Guo C.; Si X.; Chen Z.; Li J.; Chen R.; Bie Z.; De Gigl...io A.; Christopoulos P.; Liang N.; Li S. | 2023-01-01 | TRANSLATIONAL LUNG CANCER RESEARCH | - | 1.01 Articolo in rivista | 80018-PB6-4841-R2.pdf; 2322.zip |
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease | Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.;... Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | - |
Advanced non-small-cell lung cancer: how to manage non-oncogene disease | De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | dic.2022-2-4.pdf |
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience | Ricciuti B.; Baglivo S.; De Giglio A.; Chiari R. | 2018-01-01 | THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE | - | 1.01 Articolo in rivista | ricciuti-et-al-2018-afatinib-in-the-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-clinical-evidence.pdf |
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances | Tateo V.; Manuzzi L.; Parisi C.; De Giglio A.; Campana D.; Pantaleo M.A.; Lamberti G. | 2021-01-01 | PHARMACEUTICALS | - | 1.01 Articolo in rivista | pharmaceuticals-14-00316.pdf |
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events | Cortellini A.; Bersanelli M.; Santini D.; Buti S.; Tiseo M.; Cannita K.; Perrone F.; Giusti R.; D...e Tursi M.; Zoratto F.; Marconcini R.; Russano M.; Zeppola T.; Anesi C.; Filetti M.; Marchetti P.; Botticelli A.; Gelibter A.; De Galitiis F.; Vitale M.G.; Rastelli F.; Tudini M.; Silva R.R.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Migliorino M.R.; Mallardo D.; Vanella V.; Mosillo C.; Bracarda S.; Rinaldi S.; Berardi R.; Natoli C.; Ficorella C.; Porzio G.; Ascierto P.A. | 2020-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
Antibody–drug conjugates for lung cancer in the era of personalized oncology | Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R....; Pirro M. | 2021-01-01 | SEMINARS IN CANCER BIOLOGY | - | 1.01 Articolo in rivista | - |
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer | Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Prelaj A.; Lopez-Castro R.; Bosch-Bar...rera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar Nana F.; Ponce S.; Albarran-Artahona V.; Dal Maso A.; Spotti M.; Mielgo X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.B.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Mezquita L.; Planchard D. | 2023-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials | Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G. | 2022-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach | De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients | De Giglio A.; Deiana C.; Di Federico A. | 2023-01-01 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies | de Giglio A.; Nuvola G.; Gustavo Dall'Olio F. | 2019-01-01 | TRANSLATIONAL CANCER RESEARCH | - | 1.01 Articolo in rivista | 34515-PB4-8201-R6.pdf |
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians | Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, ...Rita; Potena, Luciano | 2023-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | Raschi et al., Drug Safety Cardiotoxicity ICI 2023.pdf; 40264_2023_1320_MOESM1_ESM.pdf |
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities | De Giglio A.; Orlando V.; Andrini E.; Ricciuti B.; Lamberti G.; Chiari R. | 2022-01-01 | TUMORI | - | 1.01 Articolo in rivista | - |
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics | de Giglio A.; Nuvola G.; Baldini C. | 2020-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer | Ricciuti B.; Brambilla M.; Cortellini A.; De Giglio A.; Ficorella C.; Sidoni A.; Bellezza G.; Cri...no L.; Ludovini V.; Baglivo S.; Metro G.; Chiari R. | 2020-01-01 | CLINICAL & TRANSLATIONAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review | Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A. | 2023-01-01 | LUNG CANCER: TARGETS AND THERAPY | - | 1.01 Articolo in rivista | - |
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience | Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppion...i E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A. | 2020-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) | Naqash A.R.; Ricciuti B.; Owen D.H.; Florou V.; Toi Y.; Cherry C.; Hafiz M.; De Giglio A.; Muzaff...ar M.; Patel S.H.; Sugawara S.; Burkart J.; Park W.; Chiari R.; Sugisaka J.; Otterson G.A.; de Lima Lopes G.; Walker P.R. | 2020-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |